Apogee Therapeutics, Inc.
APGE
Rankning i aktier
#2321
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Aktiekurs
$135.07
Senast synkroniserad: 2026-09-04
Marknadsvärde
$8.36B
Förändring (1 dag)
0.00%
Förändring (1 år)
152.56%
Land
US
Handel Apogee Therapeutics, Inc. (APGE)
Kategori
Healthcare
Aktiekurshistorik för Apogee Therapeutics, Inc. (APGE)
Högsta slutkurs: $135.07 den 2026-09-01
Lägsta slutkurs: $20.79 den 2023-07-01
Lägsta slutkurs: $20.79 den 2023-07-01
Aktiekurshistorik för Apogee Therapeutics, Inc. från 2023 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 17.47% |
| 2025 | 60.85% |
| 2024 | 96.41% |
| 2023 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $536.98 | 25.92% |
US
|
|
| $224.77 | 737.11% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $876.75 | 7.69% |
NL
|
